Varvara Choida1,2, Margaret Hall-Craggs3, Bethany R Jebson1,4, Corinne Fisher1,2, Maria Leandro1,2, Lucy R Wedderburn1,4,5, Coziana Ciurtin1,2. 1. Centre for Adolescent Rheumatology Versus Arthritis at UCL UCLH and GOSH, Division of Medicine, University College London, London, United Kingdom. 2. Department of Adolescent Rheumatology, University College London Hospital, London, United Kingdom. 3. Centre for Medical Imaging, University College London, London, United Kingdom. 4. University College London Great Ormond Street Institute for Child Health, London, United Kingdom. 5. NIHR Biomedical Research Centre at Great Ormond Street Hospital, London, United Kingdom.
Abstract
Background: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory arthritis of childhood, characterized by various clinical phenotypes associated with variable prognosis. Significant progress has been achieved with the use of biologic treatments, which specifically block pro-inflammatory molecules involved in the disease pathogenesis. The most commonly used biologics in JIA are monoclonal antibodies and recombinant proteins targeting interleukins 1 (IL-1) and 6 (IL-6), and tumor necrosis factor α (TNF-α). Several biomarkers have been investigated in JIA. Aims: To assess the level of evidence available regarding the role of biomarkers in JIA related to guiding clinical and therapeutic decisions, providing disease prognostic information, facilitating disease activity monitoring and assessing biologic treatment response in JIA, as well as propose new strategies for biologic therapy-related biomarker use in JIA. Methods: We searched PubMed for relevant literature using predefined key words corresponding to several categories of biomarkers to assess their role in predicting and assessing biologic treatment response and clinical remission in JIA. Results: We reviewed serological, cellular, genetic, transcriptomic and imaging biomarkers, to identify candidates that are both well-established and widely used, as well as newly investigated in JIA on biologic therapy. We evaluated their role in management of JIA as well as identified the unmet needs for new biomarker discovery and better clinical applications. Conclusion: Although there are no ideal biomarkers in JIA, we identified serological biomarkers with potential clinical utility. We propose strategies of combining biomarkers of response to biologics in JIA, as well as routine implementation of clinically acceptable imaging biomarkers for improved disease assessment performance.
Background: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory arthritis of childhood, characterized by various clinical phenotypes associated with variable prognosis. Significant progress has been achieved with the use of biologic treatments, which specifically block pro-inflammatory molecules involved in the disease pathogenesis. The most commonly used biologics in JIA are monoclonal antibodies and recombinant proteins targeting interleukins 1 (IL-1) and 6 (IL-6), and tumor necrosis factor α (TNF-α). Several biomarkers have been investigated in JIA. Aims: To assess the level of evidence available regarding the role of biomarkers in JIA related to guiding clinical and therapeutic decisions, providing disease prognostic information, facilitating disease activity monitoring and assessing biologic treatment response in JIA, as well as propose new strategies for biologic therapy-related biomarker use in JIA. Methods: We searched PubMed for relevant literature using predefined key words corresponding to several categories of biomarkers to assess their role in predicting and assessing biologic treatment response and clinical remission in JIA. Results: We reviewed serological, cellular, genetic, transcriptomic and imaging biomarkers, to identify candidates that are both well-established and widely used, as well as newly investigated in JIA on biologic therapy. We evaluated their role in management of JIA as well as identified the unmet needs for new biomarker discovery and better clinical applications. Conclusion: Although there are no ideal biomarkers in JIA, we identified serological biomarkers with potential clinical utility. We propose strategies of combining biomarkers of response to biologics in JIA, as well as routine implementation of clinically acceptable imaging biomarkers for improved disease assessment performance.
Authors: Peter A Nigrovic; Melissa Mannion; Femke H M Prince; Andrew Zeft; C Egla Rabinovich; Marion A J van Rossum; Elisabetta Cortis; Manuela Pardeo; Paivi M Miettunen; Ginger Janow; James Birmingham; Aaron Eggebeen; Erin Janssen; Andrew I Shulman; Mary Beth Son; Sandy Hong; Karla Jones; Norman T Ilowite; Randy Q Cron; Gloria C Higgins Journal: Arthritis Rheum Date: 2011-02
Authors: Marieke H Otten; Femke H M Prince; Wineke Armbrust; Rebecca ten Cate; Esther P A H Hoppenreijs; Marinka Twilt; Yvonne Koopman-Keemink; Simone L Gorter; Koert M Dolman; Joost F Swart; J Merlijn van den Berg; Nico M Wulffraat; Marion A J van Rossum; Lisette W A van Suijlekom-Smit Journal: JAMA Date: 2011-11-06 Impact factor: 56.272
Authors: Claas H Hinze; Dirk Foell; Anne L Johnson; Steven J Spalding; Beth S Gottlieb; Paula W Morris; Yukiko Kimura; Karen Onel; Suzanne C Li; Alexei A Grom; Janalee Taylor; Hermine I Brunner; Jennifer L Huggins; James J Nocton; Kathleen A Haines; Barbara S Edelheit; Michael Shishov; Lawrence K Jung; Calvin B Williams; Melissa S Tesher; Denise M Costanzo; Lawrence S Zemel; Jason A Dare; Murray H Passo; Kaleo C Ede; Judyann C Olson; Elaine A Cassidy; Thomas A Griffin; Linda Wagner-Weiner; Jennifer E Weiss; Larry B Vogler; Kelly A Rouster-Stevens; Timothy Beukelman; Randy Q Cron; Daniel Kietz; Kenneth Schikler; Jay Mehta; Tracy V Ting; James W Verbsky; Anne B Eberhard; Bin Huang; Edward H Giannini; Daniel J Lovell Journal: Arthritis Rheumatol Date: 2019-01-24 Impact factor: 10.995
Authors: Arndt H Brachat; Alexei A Grom; Nico Wulffraat; Hermine I Brunner; Pierre Quartier; Riva Brik; Liza McCann; Huri Ozdogan; Lidia Rutkowska-Sak; Rayfel Schneider; Valeria Gerloni; Liora Harel; Maria Terreri; Kristin Houghton; Rik Joos; Daniel Kingsbury; Jorge M Lopez-Benitez; Stephan Bek; Martin Schumacher; Marie-Anne Valentin; Hermann Gram; Ken Abrams; Alberto Martini; Daniel J Lovell; Nanguneri R Nirmala; Nicolino Ruperto Journal: Arthritis Res Ther Date: 2017-01-23 Impact factor: 5.156
Authors: Lianne Kearsley-Fleet; Eleanor Heaf; Rebecca Davies; Eileen Baildam; Michael W Beresford; Helen E Foster; Taunton R Southwood; Wendy Thomson; Kimme L Hyrich Journal: Lancet Rheumatol Date: 2020-03-09
Authors: Jessica Feldt; Martin Schicht; Jessica Welss; Kolja Gelse; Stefan Sesselmann; Michael Tsokos; Eileen Socher; Fabian Garreis; Thomas Müller; Friedrich Paulsen Journal: Biomedicines Date: 2022-03-21